Answers are grounded in this paper and cite their sources.
Retrospective cohort study shows a lower relapse risk with minimal maintenance doses of methimazole, suggesting important dosing insights for clinicians.
Background Although antithyroid drugs (ATDs) are widely used as the first-line therapy for Graves’ disease, relapse after treatment discontinuation remains common. While a prolonged low-dose ATD therapy has been associated with improved remission rates, the impact of the minimal maintenance dose before discontinuation on relapse risk remains unclear. Method We conducted a retrospective cohort study using electronic medical records from a thyroid specialty hospital in Japan. Patients newly diagnosed with Graves’ disease between 2008 and 2024 who had discontinued methimazole (MMI) after receiving a minimal maintenance dose (≤2.5 mg/day) were included. Patients were categorized into four groups based on their final maintenance dose before discontinuation: 2.5 mg/day, >1.25 to ≤2.5 mg/day, 1.25 mg/day, and <1.25 mg/day. We evaluated the association between the minimal MMI dose before discontinuation and the 1-year risk of relapse using multivariable regression and propensity score–matched analyses. Results Among 4,352 eligible patients, multivariable regression showed that, compared with the 2.5 mg/day group, the 1.25 mg/day group had a significantly lower risk of relapse within 1 year (risk ratio [RR] 0.46, 95% confidence interval [CI] 0.28–0.75), and the <1.25 mg/day group had the lowest risk (RR 0.18, 95% CI 0.05–0.73). The propensity score-matched analysis, consistent with the multivariable regression, showed that the 1.25 mg/day group had a lower risk of relapse compared with the 2.5 mg/day group (RR 0.44, 95% CI 0.23–0.85; 172 matched pairs). Conclusions Lower minimum maintenance doses of MMI before discontinuation, particularly doses <2.5 mg/day, may be associated with a reduced risk of relapse in patients with Graves’ disease. Clinicians should recognize the clinical relevance of the minimum maintenance dose in the treatment of Graves’ disease.
No takes yet. Share an insight, caveat, or question.
Miyamura et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: